Colin Bristow
Stock Analyst at UBS
(1.12)
# 3,517
Out of 4,732 analysts
86
Total ratings
30.19%
Success rate
-11.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Neutral | $31 → $29 | $26.30 | +10.27% | 9 | Jan 8, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $125 → $120 | $97.92 | +22.55% | 6 | Jan 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $47 → $71 | $43.84 | +61.95% | 3 | Dec 3, 2024 | |
| GILD Gilead Sciences | Maintains: Neutral | $70 → $96 | $91.84 | +4.53% | 3 | Nov 21, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $562 → $586 | $422.00 | +38.86% | 13 | Nov 5, 2024 | |
| AMGN Amgen | Maintains: Neutral | $335 → $326 | $272.11 | +19.80% | 7 | Oct 31, 2024 | |
| BIIB Biogen | Maintains: Neutral | $234 → $202 | $140.55 | +43.72% | 10 | Oct 3, 2024 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $25 → $4 | $1.74 | +129.89% | 4 | Aug 16, 2024 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $14 → $6 | $1.65 | +263.64% | 3 | Aug 15, 2024 | |
| IMVT Immunovant | Maintains: Buy | $42 → $41 | $23.86 | +71.84% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $1 | $0.34 | +190.70% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $681.58 | +61.24% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $7.14 | +418.21% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $56 → $54 | $10.31 | +423.76% | 2 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $118.00 | +41.53% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $725.72 | -42.13% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $9.33 | -78.56% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $1.66 | +984.34% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $171.56 | -14.90% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $56.29 | +33.24% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $3.94 | +559.90% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $6.67 | +35.03% | 1 | Aug 23, 2021 |
Pfizer
Jan 8, 2025
Maintains: Neutral
Price Target: $31 → $29
Current: $26.30
Upside: +10.27%
Merck & Co.
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $97.92
Upside: +22.55%
PTC Therapeutics
Dec 3, 2024
Maintains: Buy
Price Target: $47 → $71
Current: $43.84
Upside: +61.95%
Gilead Sciences
Nov 21, 2024
Maintains: Neutral
Price Target: $70 → $96
Current: $91.84
Upside: +4.53%
Vertex Pharmaceuticals
Nov 5, 2024
Maintains: Buy
Price Target: $562 → $586
Current: $422.00
Upside: +38.86%
Amgen
Oct 31, 2024
Maintains: Neutral
Price Target: $335 → $326
Current: $272.11
Upside: +19.80%
Biogen
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $140.55
Upside: +43.72%
ALX Oncology Holdings
Aug 16, 2024
Maintains: Buy
Price Target: $25 → $4
Current: $1.74
Upside: +129.89%
Acumen Pharmaceuticals
Aug 15, 2024
Maintains: Buy
Price Target: $14 → $6
Current: $1.65
Upside: +263.64%
Immunovant
Aug 13, 2024
Maintains: Buy
Price Target: $42 → $41
Current: $23.86
Upside: +71.84%
Aug 9, 2024
Maintains: Neutral
Price Target: $3.5 → $1
Current: $0.34
Upside: +190.70%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $681.58
Upside: +61.24%
Mar 28, 2024
Initiates: Buy
Price Target: $37
Current: $7.14
Upside: +418.21%
Mar 1, 2024
Maintains: Buy
Price Target: $56 → $54
Current: $10.31
Upside: +423.76%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $118.00
Upside: +41.53%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $725.72
Upside: -42.13%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $9.33
Upside: -78.56%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $1.66
Upside: +984.34%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $171.56
Upside: -14.90%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $56.29
Upside: +33.24%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $3.94
Upside: +559.90%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $6.67
Upside: +35.03%